Gain Therapeutics Shares Are Trading Higher After the Company Announced He Presentation of a Poster That Details the Use of Its Magellan Drug Discovery Platform to Identify Allosteric Inhibitors Targeting Discoidin Domain Receptor 2.

Benzinga13:17 ET

12 Health Care Stocks Moving In Tuesday's After-Market Session

BenzingaOct 15 16:30 ET

Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

GlobeNewswireOct 15 07:00 ET

Gain Therapeutics to Present at Michael J. Fox Foundation's 16th Annual Parkinson's Disease Therapeutics Conference

GlobeNewswireOct 9 08:30 ET

Gain Therapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow JonesOct 9 07:24 ET · Ratings

Gain Therapeutics Excels in Neurodegenerative Drug Trials

TipRanksOct 8 16:57 ET